PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte Announces Pricing of Public Offering of Common Stock
WEST LAFAYETTE, Ind. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the pricing of an underwritten registered public offering of 17,857,143 shares of its
View HTML
Toggle Summary Endocyte Announces Proposed Public Offering of Common Stock
WEST LAFAYETTE, Ind. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today that it intends to offer and sell shares of its common stock in an underwritten registered public
View HTML
Toggle Summary Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors
– Patrick Machado , Co-founder and Former Chief Business and Financial Officer of Medivation, Brings Significant Experience in Building Value in the Prostate Cancer Space – WEST LAFAYETTE, Ind. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing
View HTML
Toggle Summary Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial
WEST LAFAYETTE, Ind. and MUNICH, Germany, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced a supply agreement under which ITM will supply to Endocyte the medical radioisotope
View HTML
Toggle Summary Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results
– Phase 3 VISION Trial Design Finalized for 177 Lu-PSMA-617 Following Successful End of Phase 2 Meeting with the FDA –                    –  Announced Agreement for Clinical Supply of No-Carrier-Added Lutetium with ITM – – Added Experienced Clinical Trial Professionals to Support Execution of
View HTML
Toggle Summary Endocyte Announces Fourth Quarter and Full Year 2017 Earnings Conference Call
West Lafayette, Ind. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Feb. 26th , at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
View HTML
Toggle Summary Endocyte Added to NASDAQ Biotechnology Index  
WEST LAFAYETTE, Ind. , Dec. 15, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,  today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI).
View HTML
Toggle Summary Endocyte to Present at the Jefferies 2017 London Healthcare Conference
WEST LAFAYETTE, Ind. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company's management team will present at the Jefferies 2017 London Healthcare Conference
View HTML
Toggle Summary Endocyte Reports Third Quarter Financial Results
        - Plans to Initiate Phase 3 Registration for 177 Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte -       - The University of Sydney and ANZUP Cancer Trial Group Set to Initiate Trial of 177 Lu-PSMA-617 versus
View HTML
Toggle Summary Endocyte Announces Third Quarter 2017 Earnings Conference Call
WEST LAFAYETTE, Ind. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Nov. 6th , at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update.
View HTML